These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25908961)

  • 1. Treating medullary thyroid cancer in the age of targeted therapy.
    Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ
    Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
    Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of vandetanib in the management of medullary thyroid cancer.
    Brassard M; Rondeau G
    Biologics; 2012; 6():59-66. PubMed ID: 22500115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
    Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
    Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V; Kumar M; Chen AY; Owonikoko TK
    Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.
    Giunti S; Antonelli A; Amorosi A; Santarpia L
    Int J Endocrinol; 2013; 2013():803171. PubMed ID: 23509459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent Updates on the Management of Medullary Thyroid Carcinoma.
    Kim BH; Kim IJ
    Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 12. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
    Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
    Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
    Martins RS; Jesus TT; Cardoso L; Soares P; Vinagre J
    J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric Medullary Thyroid Carcinoma.
    Starenki D; Park JI
    J Pediatr Oncol; 2015; 3(2):29-37. PubMed ID: 27014708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.
    Almeida MQ; Hoff AO
    Curr Opin Oncol; 2012 May; 24(3):229-34. PubMed ID: 22343387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
    J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
    Hadoux J; Schlumberger M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs for medullary thyroid cancer: new promises?
    Spitzweg C; Morris JC; Bible KC
    Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib for the treatment of metastatic medullary thyroid cancer.
    Degrauwe N; Sosa JA; Roman S; Deshpande HA
    Clin Med Insights Oncol; 2012; 6():243-52. PubMed ID: 22723734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.